Erratum to: The Role of Genetics in Nicotine Dependence: Mapping the Pathways from Genome to Syndrome
- PDF / 91,057 Bytes
- 2 Pages / 595.276 x 790.866 pts Page_size
- 58 Downloads / 214 Views
ERRATUM
Erratum to: The Role of Genetics in Nicotine Dependence: Mapping the Pathways from Genome to Syndrome James MacKillop & Ezemenari M. Obasi & Michael T. Amlung & John E. McGeary & Valerie S. Knopik
Published online: 10 November 2010 # Springer Science+Business Media, LLC 2010
Erratum to: Curr Cardiovasc Risk Rep (2010) 4:446–453 DOI 10.1007/s12170-010-0132-6 The original version of this article unfortunately contained mistakes in Fig. 1. The word “continine” is misspelled two times. It should be spelled as “cotinine”. The corrected Fig. 1 is given on the next page.
The online version of the original article can be found at http://dx.doi. org/10.1007/s12170-010-0132-6. J. MacKillop (*) : M. T. Amlung Department of Psychology, University of Georgia, Athens, GA, USA e-mail: [email protected] M. T. Amlung e-mail: [email protected] J. MacKillop Center for Alcohol and Addiction Studies, Brown University, Providence, RI, USA E. M. Obasi Department of Counseling and Human Development Services, University of Georgia, Athens, GA, USA e-mail: [email protected]
J. E. McGeary Substance Abuse Treatment Program, Providence Veterans Administration Medical Center, Providence, RI, USA e-mail: [email protected] J. E. McGeary : V. S. Knopik Division of Behavioral Genetics, Department of Psychiatry, Rhode Island Hospital, Providence, RI, USA V. S. Knopik e-mail: [email protected] J. E. McGeary : V. S. Knopik Department of Psychiatry and Human Behavior, Brown University, Providence, RI, USA
108
Curr Cardiovasc Risk Rep (2011) 5:107–108
Nicotine N’-oxide
FMO3
Opioidergic activity
OPRM1
Nicotine Glutamatergic activity CYP2A6 CYP2B6
Nicotine Nglucuronide
Cotinine
nAChR activity trans-3’hydroxycotinine
trans-3’hydroxycotinine O-glucuronide
Cotinine Nglucuronide
UGT2B10
UGT2B7
Fig. 1 A model of the role of genetics in nicotine dependence via alterations to nicotine’s pharmacokinetics and pharmacodynamics. Using continuous arrows, the pharmacokinetic pathways reflect the metabolic transformations of nicotine that determine its central and peripheral nervous system bioavailability and the pharmacodynamic pathways reflect nicotine’s molecular pharmacological effects on
CHRNA4 CHRNA3 CHRNA5 CHRNB4
γ-aminobutyric acid activity
Dopaminergic activity
DBH COMT SLC6A3 DRD2 DRD3 DRD4
nicotinic acetylcholinergic receptors (nAChRs) and other neurotransmitter systems. Candidate genes and their points of putative influence are depicted using dashed arrows. Note that this is a simplified model of nicotine’s pharmacokinetics and pharmacodynamics and the candidate genes presented are illustrative examples, not an exhaustive list
Data Loading...
